{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:53:07Z","timestamp":1789840387517,"version":"4.0.1"},"reference-count":35,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The limited availability of targeted therapies in thyroid cancer (TC) has challenged conventional treatment algorithms and has established urgency for the identification of targetable genomic abnormalities. In addition to widely adopted tissue-based next-generation sequencing (NGS), plasma-based circulating tumor DNA (ctDNA) NGS is rapidly emerging as a genomic biomarker detection method and is steadily gaining utility across solid tumors. To date, plasma-based genomic alterations in TC have not been determined. Herein, we profile potential actionable mutations detected through ctDNA in patients with TC subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective data analysis of the Guardant Health, Inc. database was performed using the commercially available Guardant360\n                      <jats:sup>\u00ae<\/jats:sup>\n                      plasma-NGS test on TC samples from adult patients collected between 2016 and 2021. The landscape of genomic alterations and blood tumor mutation burden (bTMB) were analyzed in patients with different types of TC: anaplastic TC (ATC), papillary TC (PTC), follicular TC (FTC), oncolytic carcinoma of the thyroid (OCA), poorly differentiated TC (PDTC), medullary TC (MTC), and TC not otherwise specified (TC NOS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 1094 patients included most of the patients\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009876 had TC NOS, and 20% had a specific diagnosis (92 ATC, 62 PTC, 14 FTC, 16 OCA, 2 PDTC, and 32 MTC patients). The median age was 65 (range 10\u201398) and 47.3% were male. 78.3% of patients had one or more genomic alteration detected by ctDNA NGS.\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      (46.9%) was the most common mutation detected among all TC.\n                      <jats:italic toggle=\"yes\">\n                        BRAF\n                        <jats:sup>V600E<\/jats:sup>\n                      <\/jats:italic>\n                      was detected in 27.2% of ATC, 35.7% of PTC, and in none of FTC.\n                      <jats:italic toggle=\"yes\">RAS<\/jats:italic>\n                      was detected in 18.5% of ATC, 11.9% of PTC, and 62.5% of FTC.\n                      <jats:italic toggle=\"yes\">RET<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      fusions were seen in 1.1%, 0.5%, and 0.2% of all TC, respectively.\n                      <jats:italic toggle=\"yes\">RET<\/jats:italic>\n                      mutations were detected in 66.7% of MTC. bTMB analysis was performed on 159 patients. The mean bTMB was higher in ATC compared with other types of TC (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0011, 0.0557, and &lt;0.0001, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Plasma-based comprehensive NGS is a promising NGS method in TC; however, future validation of the clinical utility by analysis of paired tumor and plasma samples is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2023.0204","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T08:08:58Z","timestamp":1699949338000},"page":"197-205","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing"],"prefix":"10.1177","volume":"34","author":[{"given":"Valentina D.","family":"Tarasova","sequence":"first","affiliation":[{"name":"Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Tsai","sequence":"additional","affiliation":[{"name":"Guardant Health, Inc., Redwood City, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Masannat","sequence":"additional","affiliation":[{"name":"Guardant Health, Inc., Redwood City, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Hernandez Prera","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hallanger Johnson","sequence":"additional","affiliation":[{"name":"Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Veloski","sequence":"additional","affiliation":[{"name":"Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarimar","family":"Agosto Salgado","sequence":"additional","affiliation":[{"name":"Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"McIver","sequence":"additional","affiliation":[{"name":"Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leylah M.","family":"Drusbosky","sequence":"additional","affiliation":[{"name":"Guardant Health, Inc., Redwood City, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine H.","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838"},{"issue":"8","key":"e_1_3_4_3_2","first-page":"1556","article-title":"Multivariate analysis of patients with medullary thyroid carcinoma","volume":"77","author":"Dottorini ME","year":"1996","unstructured":"Dottorini ME, , Assi A, , Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer, 1996; 77(8):1556\u20131565.","journal-title":"Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer"},{"issue":"9","key":"e_1_3_4_4_2","first-page":"5888","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: A SEER database analysis","volume":"11","author":"Lin B","year":"2019","unstructured":"Lin B, , Ma H, , Ma M, et al. The incidence and survival analysis for anaplastic thyroid cancer: A SEER database analysis. Am J Transl Res, 2019; 11(9):5888\u20135896.","journal-title":"Am J Transl Res"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00504"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102380"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00822-7"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-1259"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6785"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00120-0"},{"key":"e_1_3_4_12_2","unstructured":"Guidelines N. Thyroid Carcinoma. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1470 [Last accessed: March30 2023]."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0944"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209288"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27025"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0624"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0322"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01039"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0076"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0296"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147707"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0237"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3771"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy269.129"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.050"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0373"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.09.030"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2005.15.531"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3362"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409405"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0514"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2023.0204","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2023.0204","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2023.0204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:18:29Z","timestamp":1787138309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2023.0204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1089\/thy.2023.0204"],"URL":"https:\/\/doi.org\/10.1089\/thy.2023.0204","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}